| abstract |
The invention relates to the use of 1H-indazole-3-carboxamide compounds as inhibitors of glycogen synthase kinase 3-beta (GSK-3β) and to their use in the treatment of GSK-3β-related diseases, such as, for example, (i) insulin-resistant disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) malignant disorders; (vi) inflammation; (vii) substance abuse disorders; (viii) epilepsy. |